GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (HKSE:01099) » Definitions » EBITDA Margin %

Sinopharm Group Co (HKSE:01099) EBITDA Margin % : 3.52% (As of Dec. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sinopharm Group Co's EBITDA for the six months ended in Dec. 2024 was HK$10,876 Mil. Sinopharm Group Co's Revenue for the six months ended in Dec. 2024 was HK$309,391 Mil. Therefore, Sinopharm Group Co's EBITDA margin for the quarter that ended in Dec. 2024 was 3.52%.


Sinopharm Group Co EBITDA Margin % Historical Data

The historical data trend for Sinopharm Group Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co EBITDA Margin % Chart

Sinopharm Group Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.96 4.74 4.75 4.51 3.67

Sinopharm Group Co Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.97 4.20 4.83 3.83 3.52

Competitive Comparison of Sinopharm Group Co's EBITDA Margin %

For the Medical Distribution subindustry, Sinopharm Group Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinopharm Group Co's EBITDA Margin % Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's EBITDA Margin % falls into.


;
;

Sinopharm Group Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Sinopharm Group Co's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=22921.455/624062.788
=3.67 %

Sinopharm Group Co's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=10875.863/309391.207
=3.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinopharm Group Co  (HKSE:01099) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Sinopharm Group Co EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinopharm Group Co Business Description

Traded in Other Exchanges
Address
No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
Executives
Citic Securities Company Limited 2201 Interest of corporation controlled by you
Zhong Xin Zheng Quan Yun Fan Dan Yi Zi Chan Guan Li Ji Hua 2501 Other
Zhong Xin Zheng Quan Zi Chan Guan Li You Xian Gong Si 2102 Investment manager
Lazard Asset Management Llc 2102 Investment manager
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Citigroup Inc. 2502 Approved lending agent
Fmr Llc 2201 Interest of corporation controlled by you
Blackrock, Inc. 2201 Interest of corporation controlled by you

Sinopharm Group Co Headlines

No Headlines